PPC
ALNY icon

Park Place Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Park Place Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.7K Buy
328
+38
+13% +$11.5K 0.02% 320
2026
Q1 		$96K Buy
290
+164
+130% +$55.8K 0.02% 271
2025
Q4 		$50.1K Hold
126
– – 0.01% 331
2025
Q3 		$57.5K Buy
+126
New +$51.3K 0.01% 307
2023
Q4 		– Sell
-49
Closed -$8.68K – 861
2023
Q3 		$8.68K Hold
49
– – ﹤0.01% 778
2023
Q2 		$9.31K Hold
49
– – ﹤0.01% 777
2023
Q1 		$9.82K Sell
49
-10
-17% -$2.1K ﹤0.01% 763
2022
Q4 		$14K Buy
+59
New +$12.6K ﹤0.01% 712

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Place Capital's ALNY Position: Q2 2026 in Review

Park Place Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $11.5K and bringing the position to 328 shares worth $98.7K. The position accounts for 0.02% of the portfolio, ranked #320.

Park Place Capital first reported a position in ALNY in Q4 2022 and has held it in 8 quarters since. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Park Place Capital held 328 shares of Alnylam Pharmaceuticals worth $98.7K as of Q2 2026.
  • Park Place Capital bought 38 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Alnylam Pharmaceuticals made up 0.02% of Park Place Capital's portfolio in Q2 2026, its #320 holding.
  • Park Place Capital first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.